News Daily News New on the Scene Nonstatin Drugs: Experts Provide Guidance Caitlin E. Cox August 31, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill Shelley Wood August 23, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Daily News Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression Michael O'Riordan August 08, 2022
News Daily News Meat Consumption and Gut Microbiome Linked to ASCVD Risk Yael L. Maxwell August 03, 2022
News Daily News USPSTF Recommends Behavior Counseling to Improve Diet and Exercise Habits Michael O'Riordan July 27, 2022
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022
News Daily News Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines Michael O'Riordan July 06, 2022
News Daily News ‘Code Blue’ for the Dire CVD Health Status of Most US Adults Michael O'Riordan July 05, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022